Haematology

Dr. Öğr. Üyesi Süreyya Yiğit Kaya

Doctor and researcher Medipol Mega Üniversite Hastanesi İstanbul
Multiple MyelomaGraft vs Host Disease
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Multiple Myeloma 3 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Graft vs Host Disease 2 publications

Person ↔ Disease

Which topics does this doctor work on?

From source

Medical areas of interest stated by the doctor on the institution profile. Source: medipol.com.tr.

  • Akut ve kronik lösemiler
  • Lenfomalar
  • Multiple miyelom
  • Hematopoetik kök hücre nakli ve nakil sonrası hematolojik komplikasyonlar
  • Anemiler
  • Trombositopeni ve trombosit hastalıkları
  • Koagülasyon bozuklukları
  • Hemoglobinopatiler
  • Kemik iliği yetmezlikleri
  • Miyeloproliferatif hastalıklar
  • Miyelodisplastik sendromlar

CV

Education and experience

From source

Dr. Öğr. Gör. Süreyya Yiğit Kaya, 1984 yılında Elazığ’da doğmuştur, aslen Malatyalıdır. Tıp eğitimini İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi’nde 2008 yılında tamamlamıştır. İç Hastalıkları uzmanlık eğitimini İstanbul Medeniyet Üniversitesi Göztepe Eğitim ve Araştırma Hastanesi’nde 2013 yılında, Hematoloji yandal uzmanlık eğitimini ise Dokuz Eylül Üniversitesi Tıp Fakültesi’nde 2017 yılında tamamlamıştır.

Uzmanlık eğitimi sonrasında Sivas Şarkışla Devlet Hastanesi (İç Hastalıkları Uzmanı), Batman Bölge Devlet Hastanesi (Hematoloji Uzmanı) ve Manisa Şehir Hastanesi’nde (Hematoloji Uzmanı) görev yapan Dr. Süreyya Yiğit Kaya, 2022 yılından itibaren Medipol Mega Hastanesi’nde Doktor Öğretim Görevlisi olarak çalışmalarını sürdürmektedir.

Ulusal ve uluslararası hakemli dergilerde yayımlanmış çok sayıda makalesi, bilimsel toplantılarda sunulmuş bildirileri, kitap bölümleri ve olgu sunumları bulunmaktadır. 2026 Mart ayında Türk Hematoloji Derneği Akut Lenfoblastik Lösemi Bilimsel Alt Komitesi (B-ALL Çalışma Grubu) sekreterliği görevine atanmıştır.

Education

  • 2017Dokuz Eylül Üniversitesi Tıp Fakültesi, Hematolojimedipol.com.tr
  • 2013İstanbul Medeniyet Üniversitesi Göztepe Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniğimedipol.com.tr
  • 2008İstanbul Üniversitesi Cerrahpaşa, Tıp Fakültesimedipol.com.tr

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyHaematologymedipol.com.trFrom source
  • InstitutionMedipol Mega Üniversite Hastanesimedipol.com.trFrom source
  • Area of workMultiple MyelomaExtracted from 3 publications · Model version —From source
  • Publications56 publicationsOpenAlexFrom source
  • Languagesİngilizcemedipol.com.trFrom source
  • Last synchronised4 November 2026 20:23https://medipol.com.tr/doktorlarimiz/doktor-ogretim-uyesi-sureyya-yigit-kayamedipol.com.tr

Scientific work

Publications on Multiple Myeloma

56 publications

  1. Universal Use of Novel Oral Anticoagulant Prophylaxis in Myeloma Patients Undergoing IMiD-Based Therapy: Real-World Experience

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020453 PMID 41598391 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  2. Venetoclax-based treatment in adult relapsed/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma: a single-center real-world experience

    Journal of Health Sciences and Medicine, 2026

    DOI 10.32322/jhsm.1825832 Open-access full textSource: OpenAlex

  3. Long-Term Complete Remission Following Lenalidomide-Augmented IVAC/ICE Therapy and Allogeneic Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Case Report

    Turkish Journal of Hematology, 2026

    DOI 10.4274/tjh.galenos.2026.13284 PMID 41914439 Open-access full textSource: OpenAlex

  4. Real-World Experience with Belinostat in the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma

    Annals of Medical Research, 2026

    DOI 10.5455/annalsmedres.2025.07.193 Open-access full textSource: OpenAlex

  5. Direct Second Autologous Stem Cell Transplantation Versus Re-Induction Followed by Transplantation in Relapsed Multiple Myeloma: A Multicenter Real-World Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15135045 PMID 42452507 Open-access full textSource: OpenAlex

  6. A Multi-Targeted Strategy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Real-World Outcomes of the ViPOR Regimen

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15145401 PMID 42513315 Open-access full textSource: OpenAlex

  7. Enterovirus Encephalitis Developing After Treatment for Follicular Lymphoma: A Case Report

    SN Comprehensive Clinical Medicine, 2026

    DOI 10.1007/s42399-026-02560-z Source: OpenAlex

  8. Evaluation of the frequency, risk factors, and outcomes of splanchnic vein thrombosis in myeloproliferative neoplasms: a retrospective cohort study

    Journal of Thrombosis and Thrombolysis, 2026

    DOI 10.1007/s11239-026-03363-8 PMID 42565930 Open-access full textSource: OpenAlex

  9. Real-World Effectiveness and Renal Safety of Foscarnet for CMV Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15166365 PMID 42652768 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  10. Real-World Outcomes of Belinostat in Relapsed Refractory T-Cell Lymphomas: A Report from the Lymphoma Study Group of Turkish Society of Hematology

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15166350 PMID 42652754 Open-access full textSource: OpenAlex

View all 56 publications